Michael Osterholm博士告诉财富杂志,Novavax有可能提供比目前的 mRNA疫苗更长更广泛的保护.

来源: 5181 2022-09-17 19:35:35 [] [旧帖] [给我悄悄话] 本文已被阅读: 次 (5947 bytes)

https://fortune.com/well/2022/09/17/america-skeptical-novavax-popular-abroad-covid-vaccine-covid19-omicron-booster-coroanvirus-pandemic-epidemic-endemic-cdc-fda/

“What excited some people about it is the fact that it’s very similar to a lot of vaccines produced in the past,” Swartzberg said. “Protein vaccines have been used for decades. For some people, that gives them a degree of comfort, based upon emotion and not science.”

Novavax has the potential to offer longer, broader protection than current mRNA vaccines, Dr. Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), told Fortune.

But more data on the vaccine is needed to determine the length of protection it offers, as well as its performance against Omicron subvariants. 

“I think it could be a better vaccine,” Osterholm said, though he cautioned that, in the early days of mRNA COVID vaccines, society had “unbridled expectations that ultimately didn’t pan out,” such as the vaccines preventing infection.

Like mRNA vaccines, Novavax protects against severe COVID outcomes like hospitalization and death. But it doesn’t prevent infection or transmission, according to Yale Medicine.

Maryland-based Novavax began developing its COVID vaccine in 2020, during Operation Warp Speed, but manufacturing difficulties slowed progress. Countries began granting the vaccine approval in November.

In the U.S., the two-dose shot series is approved for those 12 and older, with shots occurring three to eight weeks apart. Side effects are similar to mRNA COVID vaccines and include tenderness, pain, and/or swelling at the injection site, fatigue, muscle pain, joint pain, headache, nausea, vomiting, and/or fever, according to Yale Medicine. As is the case with mRNA COVID vaccines, myocarditis—a rare form of heart inflammation—has been reported, though rarely.

Dr. Bali Pulendran, professor of microbiology and immunology at Stanford University, told Fortune he isn’t sure why the U.S. hasn’t yet approved Novavax for use as a booster, giving those who’ve received a two-dose mRNA series another option, aside from newly approved Omicron mRNA vaccines.

The U.S. Food and Drug Administration didn’t immediately respond to Fortune’s question as to why the U.S. hasn’t approved the vaccine for use as a booster, though other countries have.

“It’s a terrific vaccine, and I do hope people get access to it if they wish to,” Pulendran said.

 

所有跟帖: 

有可能就等于没有。 -AprilMei- 给 AprilMei 发送悄悄话 AprilMei 的博客首页 (0 bytes) () 09/17/2022 postreply 21:11:07

需要统计来证明.蛋白疫苗和mRNA打入后工作原理不一样. -5181- 给 5181 发送悄悄话 (0 bytes) () 09/18/2022 postreply 07:06:29

前天看到文章说在美国不受欢迎,只有不到七千人打,但在许多欧亚国家受欢迎 -dudaan- 给 dudaan 发送悄悄话 dudaan 的博客首页 (0 bytes) () 09/18/2022 postreply 06:11:26

1.是知道人少2.供应药店少.3.受宣传影响,好多人即使感染1,2次以上还信mRNA能防重症之说,而不是病毒毒性降低. -5181- 给 5181 发送悄悄话 (0 bytes) () 09/18/2022 postreply 07:01:34

请您先登陆,再发跟帖!

发现Adblock插件

如要继续浏览
请支持本站 请务必在本站关闭/移除任何Adblock

关闭Adblock后 请点击

请参考如何关闭Adblock/Adblock plus

安装Adblock plus用户请点击浏览器图标
选择“Disable on www.wenxuecity.com”

安装Adblock用户请点击图标
选择“don't run on pages on this domain”